Alpha Profiles · Company Profile

Lakewood-Amedex Biotherapeutics Inc.

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies.

https://registry.alpha.ac/companies/lakewood-amedex-biotherapeutics-inc

Entity: Public listing published
Primary listing: NASDAQ: LABT
Verification: Partially verified
Last reviewed: 2026-10-23T04:48:16.793914+00:00

Overview

This biopharmaceutical company is dedicated to developing innovative antimicrobial therapies. Its array of anti-infective products is designed to tackle specific viral conditions, including avian influenza, Epstein-Barr Virus (EBV), and hepatitis B and C. Established by Roderic Dale on July 11, 2006, the firm maintains its principal office in Bradenton, Florida.

Canonical AEGIS identity graph

Executive leadership

Current, confirmed roles are shown only when both the person Profile and supporting source record satisfy the public projection boundary. A missing role is not evidence that it does not exist.

Executive team

3 public records

Kelvin Cooper

Chief Executive Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001213900-26-087336Aug 10, 2026

Peter Ceccacci

Chief Financial Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001213900-26-087336Aug 10, 2026

Thomas Balzer

Chief Medical Officer

State: confirmed
Effective: Date not stated
Confidence: 95%
Evidence: SEC DEF 14A 0001213900-26-087336Aug 10, 2026

Governance leadership

Boards & Committees

Board and committee assignments appear only when the canonical public projection retains a current role and supporting source. Unpublished records are not interpreted as absence.

Record as of Oct 23, 2026. Chair, executive office, Lead Independent Director and committee appointments retain their separate source roles. A complete board composition denominator and committee charters are not established by a partial roster.

Board roles

4 public records

Doug Manion

Director

Board chairIndependent

State: unconfirmed
Effective: From Jan 1, 2021
Confidence: 85%
Evidence: Lakewood-Amedex Biotherapeutics Inc. DEF 14A 2026-08-10Aug 10, 2026

Joseph Tucker

Director

Independent

State: unconfirmed
Effective: From Jan 1, 2026
Confidence: 85%
Evidence: Lakewood-Amedex Biotherapeutics Inc. DEF 14A 2026-08-10Aug 10, 2026

Kelvin Cooper

Director

Not independent

State: unconfirmed
Effective: From Jan 1, 2025
Confidence: 85%
Evidence: Lakewood-Amedex Biotherapeutics Inc. DEF 14A 2026-08-10Aug 10, 2026

Leonard J. DeRoma

Director

Independent

State: unconfirmed
Effective: From Jan 1, 2017
Confidence: 85%
Evidence: Lakewood-Amedex Biotherapeutics Inc. DEF 14A 2026-08-10Aug 10, 2026

Source record

Alpha canonical company public projection

Supports Company identity, Published leadership, Entity status boundary

Reviewed 2026-10-23T04:48:16.793914+00:00